Cosette to add liquids to its portfolio with deal for 2nd G&W Labs plant 

Cosette Pharmaceuticals says it has acquired a second generics manufacturing facility from G&W Laboratories. (Image by Niek Verlaan from Pixabay)

Cosette Pharmaceuticals was formed last year when it picked up the dermatology business and a creams and topicals manufacturing plant of G&W Laboratories. Now, Cosette has gone back for another of G&W’s manufacturing facilities. 

Cosette has acquired G&W’s finished dose manufacturing plant in Lincolnton, North Carolina, that makes liquids. Details of the plant and terms of the deal were not disclosed. 

G&W is unrelated to the drugmaker GW Pharma that makes the cannabis-based drug Epidiolex. 

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

The G&W plant in South Plainfield, New Jersey, that Cosette got in its initial deal last December is allowed to manufacture extended topical and suppository products to treat skin and allergy problems. But with the acquisition of the North Carolina plant, Bridgewater, New Jersey-based Cosette says it will be able to grow its business in new areas. 

“The Lincolnton facility has an excellent track record of producing liquid pharmaceuticals along with other differentiated dosage forms, and operates as a contract manufacturer across multiple presentations for select business partners,” Cosette CEO Walt Kaczmarek said in a statement

Cosette was created when private equity investor Avista Capital Partners put up the money to buy G&W’s dermatology business, which included 35 self-labeled generic topical dermatology products sold in the U.S. and the 180,000-square-foot manufacturing facility in New Jersey.  It also does some contract manufacturing.  

G&W Labs is a family-owned business that works in the creams and topicals markets. It retains a plant in Pennsylvania.

Suggested Articles

At one point, Novartis even offered up $90 apiece for the inclisiran developer but would later say even $85 was too much, a securities filing shows.

Sanofi spent months hyping its Tuesday investor event, and new CEO Paul Hudson certainly laid out a different vision for the drugmaker at the confab.

After more than 10 years as partners, Sanofi and Regeneron are splitting up their deal to comarket PCSK9 med Praluent and immunology drug Kevzara.